Kite
New CAR T Vision Coalition and roadmap report to launch at ASCO aims to double patients treated with CAR T-cell therapy by 2030
June 3, 2025Research and Development American Society of Clinical Oncology, CAR T Vision, CAR T-cell therapy, International Myeloma Foundation, Kite, Leukemia & Lymphoma Society, Oncology, blood cancer
For people living with aggressive blood cancers, CAR T-cell therapy offers hope for a longer, healthier life, and for some, …
Kite’s leukaemia cell therapy application validated by EMA
June 24, 2021EMA, Kite, leukemia
Kite has announced that their Type II variation application for a new indication to the approved license for autologous anti-CD19-transduced …
FDA approves Kite’s Yescarta therapy for follicular lymphoma
March 9, 2021Manufacturing and Production FDA, Kite, Yescarta
The FDA has granted accelerated approval to Kite’s Yescarta treatment, a medicine for adult patients with relapsed or refractory follicular …
European approval for Kite’s CAR-T therapy Tecartus in elapsed or refractory mantle cell lymphoma
December 17, 2020Sales and Marketing CAR-T, Europe, Gilead, Kite, Tecartus
Gilead-owned Kite Therapeutics has secured marketing authorisation from the European Commission for its chimeric antigen receptor (CAR) T cell therapy …
Top Ten most popular articles on Pharmafile.com this week
April 6, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, Boehringer Ingelheim, Kite, Nordic Nanovector, Pfizer, Roche, Sanofi, biotech, cystic fibrosis, drugs, pharma, pharmaceutical
Some of the biggest news this week concerns companies that are looking to move on parts of their business, but …
Gilead seals $3bn deal, hoping for off-the-shelf CAR-T
February 23, 2018Medical Communications, Sales and Marketing CAR-T, Gilead, Kite, Sangamo Therapeutics, biotech, drugs, pharma, pharmaceutical
The expense and laborious process involved in bringing CAR-T therapies to patients was used a key reason for the high …
Gilead aims to claim edge with Pfizer CAR-T combo
January 18, 2018Medical Communications, Research and Development Gilead, Kite, Yescarta, biotech, drugs, pharma, pharmaceutical
Although those in pharma often dislike any references to drugs competing with each other for market as in a ‘race’, …
Gilead makes $567m strategic acquisition for next-gen CAR-T
December 8, 2017Medical Communications, Sales and Marketing CAR-T, Cell Design Labs, Gilead, Kite, biotech, drugs, pharma, pharmaceutical
It’s only four months since Gilead completed its buy-out of Kite Pharma for $11.9 billion, but it’s already moving quickly …
Gilead completes £11.9 billion Kite Pharma acquisition
October 5, 2017Sales and Marketing CAR T, CAR-T, Gilead, Kite, acquisition, pharma, pharmaceuticals
Gilead has announced that it has completed its acquisition of Kite Pharma after the deal was announced on 28 August …
